Clayton Dubilier & Rice LLC has successfully acquired the Opella consumer health-care business from Sanofi SA for €16 billion ($17 billion), outbidding rival PAI Partners.
The integration process for Opella's product range will require significant effort and strategic planning. The involvement of the French government in the transaction adds complexity.
CD&R's ability to navigate these challenges and achieve its targeted returns in this unconventional corporate carve-out will be closely monitored by investors and market analysts.